Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà
MedNavigator.ru - Ïîèñê è ïîäáîð ëå÷åíèÿ â Ðîññèè è çà ðóáåæîì

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Ïåäèàòðèÿ > Ôîðóì äëÿ îáùåíèÿ âðà÷åé ïåäèàòðîâ

Ôîðóì äëÿ îáùåíèÿ âðà÷åé ïåäèàòðîâ Ôîðóì ïðåäíàçíà÷åí òîëüêî äëÿ îáùåíèÿ âðà÷åé ìåæäó ñîáîé. Âîïðîñû ïàöèåíòîâ çàäàþòñÿ íà ôîðóìå Ïåäèàòðèÿ.

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #211  
Ñòàðûé 14.11.2019, 20:56
Àâàòàð äëÿ Igoryaka
Igoryaka Igoryaka âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 29.07.2018
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 4,111
Ñêàçàë(à) ñïàñèáî: 109
Ïîáëàãîäàðèëè 2,593 ðàç(à) çà 2,500 ñîîáùåíèé
Igoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Íåò, íå óìåþ.

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Ï.Ñ. Ñïàñèáî çà èíôîðìàöèþ
__________________
Ñ óâàæåíèåì, Èãîðü Àëåêñàíäðîâè÷
Îòâåòèòü ñ öèòèðîâàíèåì
  #212  
Ñòàðûé 17.11.2019, 12:39
Àâàòàð äëÿ eduardshraibman
eduardshraibman eduardshraibman âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 20.10.2010
Ãîðîä: hadera
Ñîîáùåíèé: 17,871
Ñêàçàë(à) ñïàñèáî: 15
Ïîáëàãîäàðèëè 9,328 ðàç(à) çà 8,902 ñîîáùåíèé
eduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Tonsillectomy and/or adenoidectomy in children: Indications and contraindications.Literature review current through: Oct 2019

SUMMARY AND RECOMMENDATIONS

●Tonsillectomy and adenoidectomy are among the most common surgical procedures performed in children. Adenotonsillectomy is often thought of, and most often carried out, as a single, combined operation; however, in assessing indications for surgery, the two components require consideration individually. The two major categories of indications for tonsillectomy and/or adenoidectomy include obstruction and recurrent infection. (See 'Introduction' above.)


●Decisions regarding elective tonsillectomy and/or adenoidectomy should be individualized according to the potential benefits and risks, the natural course of the disease, and the values and preferences of the family and child. (See 'General considerations' above.)


●Adenotonsillectomy is considered the first-line treatment for obstructive sleep apnea in otherwise healthy children over two years of age with adenotonsillar hypertrophy. (See "Adenotonsillectomy for obstructive sleep apnea in children".)


●The benefits of tonsillectomy (with or without adenoidectomy) in patients with recurrent throat infections depend on the frequency and severity of previous episodes. For children with recurrent throat infection who are severely affected (ie, ≥7 episodes in one year, ≥5 episodes in each of two years, or ≥3 episodes in each of three years), we suggest tonsillectomy (with or without adenoidectomy) as an option (Grade 2B). However, given the natural decline in tonsil-related problems with increasing age, watchful waiting and provision of symptomatic care and antimicrobial treatment (as indicated) for recurrent episodes is a reasonable alternative to surgery. For children with recurrent throat infection who are only mildly or moderately affected, we suggest not performing tonsillectomy (Grade 2B). (See 'Recurrent throat infection' above and "Treatment and prevention of streptococcal pharyngitis" and "Acute pharyngitis in children and adolescents: Symptomatic treatment".)


●Tonsillectomy is a treatment option in children with the syndrome of periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) who have not responded to conservative treatment. (See "Periodic fever with aphthous stomatitis, pharyngitis, and adenitis (PFAPA syndrome)".)


●Tonsillectomy may be warranted in patients with peritonsillar abscess (PTA) who have significant upper airway obstruction or previous episodes of recurrent pharyngitis or PTA. (See "Peritonsillar cellulitis and abscess".)


●Other conditions in which tonsillectomy (with or without adenoidectomy) may be performed include the following (see 'Other conditions' above):


•Tonsillar obstruction of the oropharynx that interferes with swallowing or that alters voice quality.


•Malignant tumor of the tonsil.


•Uncontrollable hemorrhage from tonsillar blood vessels.


•Halitosis, refractory to other measures.


•Chronic (as distinct from recurrent acute) tonsillitis unresponsive to antimicrobial treatment.


•Chronic pharyngeal carriage of group A beta-hemolytic streptococci in a child who has had or is in close contact with a person who has had rheumatic heart disease, who had at least two well documented episodes of streptococcal throat infection within the preceding year, and in whom treatment with antimicrobials has not been successful in eradicating the organism.


●For children with adenoidal hypertrophy and associated moderate nasal obstructive symptoms (mouth breathing, hyponasal speech, impaired olfaction) that have been present for ≥1 year without an adequate response to conservative measures (including antimicrobial treatment for one month and/or nasal glucocorticoids for six weeks to six months), we suggest adenoidectomy rather than ongoing conservative management (Grade 2C). (See 'Nasal obstruction' above.)


●We suggest adenoidectomy for children with chronic sinusitis that has not responded adequately to medical treatment (Grade 2C). The efficacy of adenoidectomy in such children is variable. (See 'Chronic sinusitis' above.)


●For children with recurrent AOM or chronic OME who have previously undergone tympanostomy tube (TT) insertion, whose tubes have been extruded, and who are undergoing repeat TT placement, we suggest adenoidectomy in addition to TT placement rather than TT placement alone (Grade 2B). We suggest not performing adenoidectomy in children with recurrent AOM or chronic OME who have not undergone TT insertion unless they have an additional distinct indication for the adenoidectomy (eg nasal obstruction, chronic adenoiditis, chronic sinusitis) (Grade 2B). (See 'Otitis media' above and "Acute otitis media in children: Prevention of recurrence", section on 'Adenoidectomy or adenotonsillectomy' and "Otitis media with effusion (serous otitis media) in children: Management", section on 'Adenoidectomy'.)


●There are three general categories of contraindications to tonsillectomy and/or adenoidectomy: velopharyngeal, hematologic, and infectious. Patients should be assessed for these conditions prior to proceeding with surgery

Êîììåíòàðèè ê ñîîáùåíèþ:
Dr.Vad îäîáðèë(à):
ggg650 îäîáðèë(à):
Igoryaka îäîáðèë(à):
Îòâåòèòü ñ öèòèðîâàíèåì
  #213  
Ñòàðûé 05.12.2019, 00:29
Àâàòàð äëÿ Igoryaka
Igoryaka Igoryaka âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 29.07.2018
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 4,111
Ñêàçàë(à) ñïàñèáî: 109
Ïîáëàãîäàðèëè 2,593 ðàç(à) çà 2,500 ñîîáùåíèé
Igoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Âçÿòî îòñþäà (àâòîð Ñåðãåé Ìàñàëüñêèé): [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Ïîëåçíàÿ èíôîðìàöèÿ ïî ñðàâíåíèþ îñíîâíûõ àëëåðãîëîãè÷åñêèõ òåñòîâ in vivo è in vitro (êîæíûé ïðèê-òåñò è sIgE)

"Àäàïòèðîâàíî èç: Tortajada-Girbes M. et al//Eur J Pediatr; 2019; Aug 14 [Epub ahead of print]
Íàòêíóëñÿ íà èíòåðåñíîå ôîòî â îäíîé èç àäàïòèðîâàííûõ ñòàòåé.
Ìåíÿ ïîñòîÿííî ñïðàøèâàþò, ÷òî ëó÷øå ïðîáû èëè êðîâü íà àëëåðãåíû. ß íå ñîâñåì ñîãëàñåí, íî â ëþáîì ñëó÷àå â òàáëèöå åñòü ìíîãî ïîëåçíîãî.
È îñíîâíîå ýòî ðåêîìåíäàöèè êîæíûå ïðèê òåñòû îïòèìàëüíûé âàðèàíò äëÿ äåòåé, íèçêàÿ öåíà, âûñîêàÿ ÷óâñòâèòåëüíîñòü è ñïåöèôè÷íîñòü â äåòñêîì âîçðàñòå.
 áîëåå ñòàðøåì - íàðàñòàåò ðîëü ïåðåêðåñòíûõ àëëåðãåíîâ, è òàì íåîáõîäèìû ðåêîìáèíàíòíûå ìîëåêóëÿðíûå àëëåðãåíû: ISAC, íàïðèìåð.

Ðèñê àíàôèëàêñèè åñòü, íî áîëüøèíñòâî òÿæ¸ëûõ ðåàêöèé áûëî ïðè ïîñòàíîâêå áîëåå 50 òåñòîâ. [Kowalski, M. 2016 ]"

P.S. ìî¸ ïðèìå÷àíèå: íå ñîãëàñåí ñ Îöåíêîé ñâÿçè ñ êëèíè÷åñêèìè ïðîÿâëåíèÿìè

[Èçîáðàæåíèÿ äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì]

Êîììåíòàðèè ê ñîîáùåíèþ:
Dr.Vad îäîáðèë(à):
eduardshraibman îäîáðèë(à):
Ìèíèàòþðû
Íàæìèòå íà èçîáðàæåíèå äëÿ óâåëè÷åíèÿ
Íàçâàíèå: IMG-20191202-WA0020.jpg
Ïðîñìîòðîâ: 839
Ðàçìåð:	82.1 Êá
ID:	194239  
__________________
Ñ óâàæåíèåì, Èãîðü Àëåêñàíäðîâè÷
Îòâåòèòü ñ öèòèðîâàíèåì
  #214  
Ñòàðûé 05.12.2019, 09:57
Àâàòàð äëÿ eduardshraibman
eduardshraibman eduardshraibman âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 20.10.2010
Ãîðîä: hadera
Ñîîáùåíèé: 17,871
Ñêàçàë(à) ñïàñèáî: 15
Ïîáëàãîäàðèëè 9,328 ðàç(à) çà 8,902 ñîîáùåíèé
eduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
ìóêîâèñöèäîç

õîðîøåå ðóêîâîäñòâî,òåì áîëåe, ÷òî íà ðóññêîì
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Êîììåíòàðèè ê ñîîáùåíèþ:
Igoryaka îäîáðèë(à):
Îòâåòèòü ñ öèòèðîâàíèåì
  #215  
Ñòàðûé 06.12.2019, 13:39
Àâàòàð äëÿ Igoryaka
Igoryaka Igoryaka âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 29.07.2018
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 4,111
Ñêàçàë(à) ñïàñèáî: 109
Ïîáëàãîäàðèëè 2,593 ðàç(à) çà 2,500 ñîîáùåíèé
Igoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Òàêæå îòëè÷íûå êëèíè÷åñêèå ðåêîìåíäàöèè ïî ìóêîâèñöèäîçó îò Ñîþçà Ïåäèàòðîâ Ðîññèè. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Êîììåíòàðèè ê ñîîáùåíèþ:
eduardshraibman îäîáðèë(à):
Âëîæåíèÿ
Òèï ôàéëà: pdf kr_mv.pdf (591.9 Êá, 18 ïðîñìîòðîâ)
__________________
Ñ óâàæåíèåì, Èãîðü Àëåêñàíäðîâè÷
Îòâåòèòü ñ öèòèðîâàíèåì
  #216  
Ñòàðûé 13.01.2020, 11:49
Àâàòàð äëÿ eduardshraibman
eduardshraibman eduardshraibman âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 20.10.2010
Ãîðîä: hadera
Ñîîáùåíèé: 17,871
Ñêàçàë(à) ñïàñèáî: 15
Ïîáëàãîäàðèëè 9,328 ðàç(à) çà 8,902 ñîîáùåíèé
eduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
â ñâÿçè ñ ÷àñòîòîé "ãåïàòî-ñïëåíî- ïàíêðèî-ìåãàëèåé" íà ïðîñòîðàõ áûâøåãî ÑÑÑÐ ññûëêà íà íîðìy
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Êîììåíòàðèè ê ñîîáùåíèþ:
Dr.Vad îäîáðèë(à):
Îòâåòèòü ñ öèòèðîâàíèåì
  #217  
Ñòàðûé 22.03.2020, 11:52
Àâàòàð äëÿ eduardshraibman
eduardshraibman eduardshraibman âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 20.10.2010
Ãîðîä: hadera
Ñîîáùåíèé: 17,871
Ñêàçàë(à) ñïàñèáî: 15
Ïîáëàãîäàðèëè 9,328 ðàç(à) çà 8,902 ñîîáùåíèé
eduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Òåñò íà àíòèÿäåðíûå àíòèòåëà (ANA)

÷àñòî ó äåòåé íàçíà÷àþòñÿ íåîïðàâäàíî àíàëèçû, ñ ïîëîæ.ðåçóëüòàòàìè ïîòîì âðà÷è íå çíàþò , ÷òî äåëàòü
Îäèí èç ïðèìåðîâ -âîò ñòàòüÿ [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
âûáîðêà ñ èíòåðíåò ïåðåâîä÷èêîì:
Òåñò íà àíòèÿäåðíûå àíòèòåëà (ANA) - ýòî òåñò, êîòîðûé ÷àñòî èñïîëüçóåòñÿ â ïåäèàòðèè. ANA äåéñòâèòåëüíî èãðàåò ðîëü â ñåðîëîãè÷åñêîì òåñòèðîâàíèè, íî îíî äîëæíî áûòü î÷åíü îãðàíè÷åííûì. Åãî ÷àñòî íàçíà÷àþò â êà÷åñòâå ñêðèíèíãîâîãî òåñòà íà ðåâìàòè÷åñêèå çàáîëåâàíèÿ â óñëîâèÿõ ïåðâè÷íîé ìåäèöèíñêîé ïîìîùè. Îäíàêî, ïîñêîëüêó îí îáëàäàåò íèçêîé ñïåöèôè÷íîñòüþ è ÷óâñòâèòåëüíîñòüþ ê áîëüøèíñòâó ðåâìàòè÷åñêèõ è ñêåëåòíî-ìûøå÷íûõ çàáîëåâàíèé ó äåòåé, åãî íå ñëåäóåò íàçíà÷àòü â êà÷åñòâå ñêðèíèíãîâîãî òåñòà äëÿ íåñïåöèôè÷åñêèõ æàëîá, òàêèõ êàê ñêåëåòíî-ìûøå÷íàÿ áîëü. Åãî ñëåäóåò èñïîëüçîâàòü òîëüêî â êà÷åñòâå äèàãíîñòè÷åñêîãî òåñòà äëÿ äåòåé ñ âåðîÿòíîé ñèñòåìíîé êðàñíîé âîë÷àíêîé (SLE) èëè ñìåøàííîé áîëåçíüþ ñîåäèíèòåëüíîé òêàíè (MCTD) è äðóãèìè âîçìîæíûìè çàáîëåâàíèÿìè, ïîõîæèìè íà ïåðåêðûòèÿ. Ó òàêèõ äåòåé äîëæíû áûëè áûòü îïðåäåëåííûå ïðèçíàêè è ñèìïòîìû çàáîëåâàíèÿ, ïðåæäå ÷åì íàçíà÷àòü ANA.  ýòîì îáçîðå ïðåäñòàâëåíû äàííûå, ïîäòâåðæäàþùèå ýòè âûâîäû, à òàêæå îáçîð ëèòåðàòóðû ANA äëÿ âçðîñëûõ è äåòåé.

Îãðàíè÷èâàÿ òåñòèðîâàíèå ANA, ïîñòàâùèêè ïåðâè÷íîé ìåäèöèíñêîé ïîìîùè ìîãóò èçáåæàòü íåíóæíîé áîëè ïðè âåíåïóíêöèè, íåíóæíûõ íàïðàâëåíèé, äîïîëíèòåëüíûõ ìåäèöèíñêèõ ðàñõîäîâ è, ÷òî íàèáîëåå âàæíî, çíà÷èòåëüíûõ ðîäèòåëüñêèõ òðåâîã. Ëó÷øå íå äåëàòü òåñò ANA ó áîëüøèíñòâà äåòåé, íî åñëè îí óïîðÿäî÷åí è èìååò ïîëîæèòåëüíûé ðåçóëüòàò ïðè íèçêîì òèòðå (<1: 640), ðåçóëüòàòû ìîãóò áûòü ïðîèãíîðèðîâàíû, åñëè ðåáåíîê â îñòàëüíîì ÷óâñòâóåò ñåáÿ õîðîøî è íå èìååò äðóãèõ ïðèçíàêîâ ñèñòåìíîãî çàáîëåâàíèÿ

Âñå ïðîâåäåííûå èññëåäîâàíèÿ ïîêàçûâàþò, ÷òî ïîëîæèòåëüíûé òåñò íà ÀÍÀ ÷àñòî îáíàðóæèâàåòñÿ â ïåäèàòðè÷åñêîé áîëüíèöå, è äàæå ïðè âûñîêîì òèòðå ó íåãî åñòü òîëüêî ïëîõàÿ ñïîñîáíîñòü îïðåäåëÿòü, åñòü ëè ó ðåáåíêà âîñïàëèòåëüíîå ðåâìàòè÷åñêîå çàáîëåâàíèå
Cabral et al. ïðîñëåäèëè êóðñ 24 äåòåé, ó êîòîðûõ êëèíè÷åñêè ñ÷èòàëîñü, ÷òî ó íèõ íåò âîñïàëèòåëüíîãî çàáîëåâàíèÿ, íåñìîòðÿ íà òî, ÷òî îíè áûëè ïîëîæèòåëüíûìè ïî ANA, è îáíàðóæèëè, ÷òî íè ó îäíîãî ïàöèåíòà íå áûëî ÿâíîãî âîñïàëèòåëüíîãî çàáîëåâàíèÿ â òå÷åíèå ïåðèîäà íàáëþäåíèÿ 61 ìåñÿö (îò 13 äî 138 ìåñÿöåâ).
 îòäåëüíîì èññëåäîâàíèè 59 ïåäèàòðè÷åñêèõ ïàöèåíòîâ ñ ôèáðîìèàëãèåé 17 (28,8%) áûëè ANA-ïîëîæèòåëüíûìè (ñðåäíèé òèòð 1: 160). Ïÿòüäåñÿò ïàöèåíòîâ íàõîäèëèñü ïîä íàáëþäåíèåì â ñðåäíåì â òå÷åíèå 18,3 ìåñÿöåâ, è çà ýòî âðåìÿ íè ó îäíîãî ïàöèåíòà íå ðàçâèëîñü çàáîëåâàíèå ñîåäèíèòåëüíîé òêàíè [18]. Èç ýòèõ ðåçóëüòàòîâ ìû ìîæåì çàêëþ÷èòü, ÷òî ëèøü â ðåäêèõ ñëó÷àÿõ ïðèñóòñòâèå ÀÍÀ ÿâëÿåòñÿ ïðåäâåñòíèêîì îêêóëüòíîé ÑÊ èëè äðóãîãî çàáîëåâàíèÿ ñîåäèíèòåëüíîé òêàíè.
Ñëåäóåò òàêæå ïîìíèòü, ÷òî ÀÍÀ ñâÿçàíû íå òîëüêî ñ êëàññè÷åñêèìè àóòîèììóííûìè çàáîëåâàíèÿìè, íî òàêæå ñ èíôåêöèåé ,çëîêà÷åñòâåííûìè íîâîîáðàçîâàíèÿìè è ëåêàðñòâåííûìè ïðåïàðàòàìè (Òàáëèöà (Table1) 1) ×òîáû ïðîèëëþñòðèðîâàòü ýòî, â èññëåäîâàíèè Jones et al., Ïðîâåäåííîì â 2006 ãîäó, áûë ïðîàíàëèçèðîâàí 71 ðåáåíîê, êîòîðûé îáðàòèëñÿ ê ðåâìàòîëîãó è ó êîòîðîãî â êîíå÷íîì èòîãå áûë äèàãíîñòèðîâàí îñòðûé ëèìôîöèòàðíûé ëåéêîç. Èç 71 ðåáåíêà, 47 áûëè ïðîâåðåíû íà òèòð ANA, âûïîëíåííûé ïîñëå íàïðàâëåíèÿ. Èç 47 äåòåé ALL 8 (17%) èìåëè ïîâûøåííûé òèòð ANA .Òåñò íå òîëüêî ÷àñòî ïîëîæèòåëüíûé ïðè íåðåâìàòè÷åñêèõ çàáîëåâàíèÿõ, íî è îòðèöàòåëüíûé ïðè ìíîãèõ ðåâìàòè÷åñêèõ çàáîëåâàíèÿõ
Òàê ÷òî æå äåëàòü ñ ïîëîæèòåëüíûì òåñòîì ANA? ... Äðóãèìè ñëîâàìè, áûëî áû ëó÷øå, åñëè áû òåñò ANA íå áûë ñäåëàí â ïåðâóþ î÷åðåäü! Ìû ïðåäïîëîæèëè áû, ÷òî ïîëîæèòåëüíûé òåñò ANA ìîæíî áåçîïàñíî èãíîðèðîâàòü, åñëè íåò äðóãèõ ñóããåñòèâíûõ êëèíè÷åñêèõ ïðèçíàêîâ è ïðîñòûõ ëàáîðàòîðíûõ òåñòîâ (òàêèõ êàê ïîâûøåííàÿ ÑÎÝ èëè öèòîïåíèÿ), êîòîðûå óêàçûâàþò íà äèàãíîç âîë÷àíêè èëè ïîäîáíîãî çàáîëåâàíèÿ ñîåäèíèòåëüíîé òêàíè, îñîáåííî åñëè ANA òèòð ìåíåå 1: 640. Ó÷èòûâàÿ âûñîêèé óðîâåíü ëîæíîïîëîæèòåëüíûõ ðåçóëüòàòîâ àíàëèçîâ ANA, ïîëîæèòåëüíûé òåñò íåëüçÿ èñïîëüçîâàòü â êà÷åñòâå ïîäòâåðæäàþùåãî äîêàçàòåëüñòâà òîãî, ÷òî ó ðåáåíêà ñ îïóõøèì ñóñòàâîì ÞÈÀ, à íå ïðè íåêîòîðûõ äðóãèõ ñåðüåçíûõ çàáîëåâàíèÿõ, òàêèõ êàê ñåïòè÷åñêèé àðòðèò, ëåéêîç èëè ãåìîôèëèÿ. Àíàëîãè÷íûì îáðàçîì, òàêèå ñèìïòîìû, êàê óñòàëîñòü, áîëè è áîëè ó ðåáåíêà, íå ñëåäóåò ïðèïèñûâàòü SLE ïðîñòî èç-çà ïîëîæèòåëüíîãî òåñòà ANA. Ãîðàçäî áîëåå âåðîÿòíî, ÷òî ó òàêîãî ðåáåíêà åñòü èäèîïàòè÷åñêèé áîëåâîé ñèíäðîì, òàêîé êàê ôèáðîìèàëãèÿ èëè ãèïåðìîáèëüíîñòü. Îòðèöàòåëüíûé àíàëèç ÀÍÀ áîëåå ïîëåçåí, ÷åì ïîëîæèòåëüíûé, ïîñêîëüêó îí ïðàêòè÷åñêè èñêëþ÷àåò äèàãíîç ÑÊ ó ðåáåíêà.

Äëÿ ýòîãî íåîáõîäèìî ïðîâåñòè èññëåäîâàíèå ýêîíîìè÷åñêîé ýôôåêòèâíîñòè, ÷òîáû îöåíèòü, ñëåäóåò ëè çàìåíèòü òåñò ANA òåñòîì íà àíòè-dsDNA è àíòè-ENA (àíòè-Sm, RNP, SSA è SSB) àíòèòåëà. Äî òåõ ïîð, ïîêà ýòî èññëåäîâàíèå íå áóäåò âûïîëíåíî, ìû áû ðåêîìåíäîâàëè, ÷òîáû íå ðåâìàòîëîãè ïðîâîäèëè òåñò ANA òîëüêî â òîì ñëó÷àå, åñëè ñóùåñòâóåò äîñòàòî÷íî âûñîêàÿ âåðîÿòíîñòü (âîçìîæíî, 10 +%) òîãî, ÷òî ñèìïòîìû ó ðåáåíêà ìîãóò áûòü ñâÿçàíû ñ SLE èëè MCTD. Åñëè òåñò ïîëîæèòåëüíûé ïðè òèòðå> 1: 160, òîãäà áûëî áû öåëåñîîáðàçíî çàêàçàòü àíòèòåëà ê äöÄÍÊ è ÝÍÀ, ïðè ýòîì èãíîðèðóþòñÿ áîëåå íèçêèå òèòðû, à òàêæå óðîâíè êîìïëåìåíòà.

Ìû íàñòîÿòåëüíî ðåêîìåíäóåì, ÷òîáû òåñò ANA íå íàçíà÷àëñÿ áåç ðàçáîðà êàê ÷àñòü «ðåâìàòîëîãè÷åñêîãî îáñëåäîâàíèÿ». Äðóãèå äåòñêèå ðåâìàòîëîãè îòìå÷àþò â ëèòåðàòóðå, ÷òî ÀÍÀ ÿâëÿåòñÿ ïëîõèì ñêðèíèíãîâûì òåñòîì è èñïîëüçóåòñÿ íå ïî íàçíà÷åíèþ .Ìû íàäååìñÿ, ÷òî äàëüíåéøàÿ äåìîíñòðàöèÿ ýòèõ ôàêòîâ ïîñòåïåííî óìåíüøèò èõ íåöåëåâîå èñïîëüçîâàíèå. Ñòîèìîñòü íåïîäõîäÿùèõ íàïðàâëåíèé, äîïîëíèòåëüíàÿ âåíåïóíêöèÿ, íåíóæíûå ðàñõîäû è ïîâûøåííàÿ ðîäèòåëüñêàÿ è äåòñêàÿ òðåâîæíîñòü - çíà÷èòåëüíàÿ ïðîáëåìà, êîòîðóþ ïåäèàòðè÷åñêèå ðåâìàòîëîãè âèäÿò êàæäûé äåíü

Êîììåíòàðèè ê ñîîáùåíèþ:
ggg650 îäîáðèë(à):
Îòâåòèòü ñ öèòèðîâàíèåì
  #218  
Ñòàðûé 29.03.2020, 10:27
Àâàòàð äëÿ eduardshraibman
eduardshraibman eduardshraibman âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 20.10.2010
Ãîðîä: hadera
Ñîîáùåíèé: 17,871
Ñêàçàë(à) ñïàñèáî: 15
Ïîáëàãîäàðèëè 9,328 ðàç(à) çà 8,902 ñîîáùåíèé
eduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
àêíå ó äåòåé .ïîäõîä â çàâèñèìîñòè îò âîçðàñòà

ïåäèàòðû îáû÷íî ñòàëêèâàþòñÿ ñ àêíå íîâîðîæäåííûõ è àêíå ïîäðîñòîâ è ÷àñòî ïëîõî îñâåäîìëåíû, ÷òî äåëàòü ñ àêíå ó äåòåé â âîçðàñòå 4-6 ìåñ èëè 5-7 ëåò.Âîò ïîïàëàñü ñòàòüÿ , êîò.íåìíîãî îáüÿñíÿåò ðàçëè÷èå ïîäõîäîâ
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Pediatric acne can be divided into five subgroups: neonatal, infantile, midchildhood, preadolescent and adolescent. Neonatal acne is common, affecting 20% of infants younger than six weeks. It is an inflammatory response to the saprophytic yeast Malassezia and is not true acne. It presents with inflammatory papules and pustules, is more common in boys, resolves by four months of age and rarely requires treatment.
Infantile acne has a similar lesion distribution and male predominance but includes comedones, nodules and cysts. In rare instances in which infantile acne is severe and persistent, or when additional signs of virilization are noted, underlying endocrinopathies must be considered. It presents later (age 3–16 mo) and is much less common, affecting less than 2% of children. Infantile acne may persist for one to two years and has been linked to an increased incidence and severity of adolescent acne.
All cases of acne presenting in midchildhood (age one to seven years) should be investigated for hyperandrogenism.
Unlike neonatal acne, infantile acne can result in scarring. The risk of scarring is difficult to estimate but increases with severity of acne and in patients with darker skin. Early and effective treatment of substantial infantile acne can reduce that risk.
Topical treatments are effective in mild cases of infantile acne consisting of comedones and pustules and include benzoyl peroxide, retinoids, azelaic acid and antibiotics. Oral antibiotics (erythromycin or trimethoprim) or oral isotretinoin can be used for severe infantile acne involving deep nodules and cysts
Îòâåòèòü ñ öèòèðîâàíèåì
  #219  
Ñòàðûé 13.05.2020, 18:44
Àâàòàð äëÿ eduardshraibman
eduardshraibman eduardshraibman âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 20.10.2010
Ãîðîä: hadera
Ñîîáùåíèé: 17,871
Ñêàçàë(à) ñïàñèáî: 15
Ïîáëàãîäàðèëè 9,328 ðàç(à) çà 8,902 ñîîáùåíèé
eduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
÷àñòî â ïîñëåäíåå âðåìÿ â àíàëèçàõ ïðèõîäÿò ðåçóëüòàòû àí.êðîâè ñ îïèñàíåì ìîðôîëîãèè êëåòîê êðîâè
Äëÿ ìåíÿ çäåñü ìíîãî íîâûõ terminov( èíîãäà íîâûå íàçâàíèÿ ïðîñòî), ìîæî ïîñìîòðåòü ññûëêó íà ðóññêîì [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Êîììåíòàðèè ê ñîîáùåíèþ:
Dr.Vad îäîáðèë(à):
Îòâåòèòü ñ öèòèðîâàíèåì
  #220  
Ñòàðûé 20.05.2020, 11:05
Àâàòàð äëÿ eduardshraibman
eduardshraibman eduardshraibman âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 20.10.2010
Ãîðîä: hadera
Ñîîáùåíèé: 17,871
Ñêàçàë(à) ñïàñèáî: 15
Ïîáëàãîäàðèëè 9,328 ðàç(à) çà 8,902 ñîîáùåíèé
eduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
äëèòåëüíûé êàøåëü ó äåòåé(íåðåäêî " íåóäîáíûå" è ïðîáëåìíûå ïàöèåíòû íà ïðèåìå ó ïåäè

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
äëèòåëüíûé êàøåëü ó äåòåé(íåðåäêî " íåóäîáíûå" è ïðîáëåìíûå ïàöèåíòû íà ïðèåìå ó ïåäèàòðîâ).
ñîêðàùåííûé ïåðåâîä çäåñü https://forums.rusmedserv.com/showth...68437&posted=1
âàæíûå íåê.ìîìåíòû;
Cough is one of the most common symptoms that patients bring to the attention of primary care clinicians. Cough can be designated as acute (<3 weeks in duration), prolonged acute cough (3 to 8 weeks in duration) or chronic (> 8 weeks in duration). The common causes are in children with post viral or pertussis like illnesses causing the cough. Persistent bacterial bronchitis typically occurs when an initial dry acute cough due to a viral infection becomes a prolonged wet cough remaining long after the febrile illness has resolved. This cough responds to a completed course of appropriate antibiotics.
...Prospective studies of acute cough in young children in general practice have suggested that about 50% recover by 10 days and 90% by 3 weeks, so 10% of children still have problems in the third to fourth weeks.

Aetiology of prolonged acute cough

The most common cause for prolonged acute cough in children is post viral or post-infectious cough. Post-infectious cough can be defined as a cough that began with symptoms related to the common cold and persists. It has a high rate of spontaneous resolution without any therapeutic intervention.
Some specific causes of prolonged acute coughing are as follows:

Infants with acute bronchiolitis
...Systematic reviews looking at the therapeutics strategies in reducing the morbidities following acute bronchiolitis showed that neither the use of inhaled glucocorticoids or leukotriene antagonists during acute bronchiolitis prevent post-bronchiolitic wheezing or cough
Pertussis infection

While infants too young to have been vaccinated are at particular risk for severe whooping cough disease there has been a recent epidemic of pertussis as a cause of prolonged acute coughing in older children and adolescents in many countries
In a community study that recruited children (5–16 years of age) coughing for longer than 2 weeks, 37% of them had serological evidence of a recent pertussis infection and the median duration of coughing was 112 days (range: 38 to 191 days)Those children who were negative to pertussis (many with mycoplasma infection) also had prolonged coughing but this was shorter than the pertussis group (median duration 58 days, range 24 to 192 days). Virtually all children in this study had complete resolution of the cough .). It is thus important to note that if a trial of treatment such as inhaled corticosteroids (ICS) had been started the ICS would have appeared to have worked but the resolution would have been due to the natural resolution that occurs.
Treatment with a macrolide antibiotic may be beneficial in pertussis but only when administered in the early stages of the disease. This is difficult to implement because the diagnosis is often not thought about until the cough has become chronic unless there is known contact with an index case. It is recommended to only treat patients aged above 1 year within 3 weeks of cough onset and infants aged less than 1 year within 6 weeks of cough onset [22]. Antibiotics decrease the duration of infectiousness and thus prevent spread [23]. If the patient is diagnosed late, antibiotics will not alter the course of the illness and, even without antibiotics, the patient should no longer be spreading pertussis
Children recovering from a complicated acute pneumonia (e.g. empyema)

At least a third of children who initially have a treated empyema are still coughing by 4 weeks with one quarter at 6 months reducing to around 3% at 12 months. Some of these patients have prolonged cough due to residual of disease and as a result will benefit from a prolonged course of antibiotics 1–4 weeks from discharge or longer
Rhinosinusitis

The criteria used to diagnose rhinosinusitis in children are nasal secretions with or without a wet or dry cough occurring longer than 10 days. Chronic rhinosinusitis is more common in those with atopy and is considered present if symptoms persist longer than 4–8 weeks. Facial pain and discomfort is not so common in children when compared with adults.

Antibiotics are generally recommended for acute bacterial sinusitis but two of the four placebo controlled clinical trials were negative. This may have resulted from including those with allergic rather than an infective cause or an inappropriate antibiotic dosage. In the other two studies using amoxicillin-clavulanate showed considerable benefit although at the cost of increased side-effects
Retained inhaled foreign body

Foreign body aspiration (FBA) is most commonly seen in children below 24 months [28]. The diagnosis should be suspected if there is a history of choking followed by prolonged cough and non-resolving pneumonia. The yield from physical examination and radiological studies in the diagnosis of FBA is relatively low but is increased when the presentation is delayed and when history is doubtful. The sensitivity and specificity for each diagnostic criterion are as follows: clinical history (63% and 32%), symptoms (68% and 53%), physical examination findings (70.5% and 63%), radiological findings (73% and 68%) and the triad of cough, wheeze and diminished breath sound (88% and 51%) respectively [29]. Delayed diagnosis may be related to an unobserved aspiration event or lack of physician awareness and has serious consequences such as chronic cough, recurrent pneumonias and eventually localised areas of bronchiectasis. The immediate management is endoscopic removal of the foreign body and this should be done in case where there is parental or clinical suspicion.
Persistent bacterial bronchitis (PBB) has been defined as the presence of a chronic wet cough with resolution of cough with appropriate antibiotics and absence of pointers suggestive of alternative specific cough [30,31] Recently, an association between PBB starting in infancy and airway malacia (tracheal, bronchial) has been described [32]. The cough of PBB resolves after a course of antibiotic such as amoxicillin-clavulanate for 2 weeks but some require a longer 4–6 weeks antibiotic. If PBB fails to respond to antibiotics or if PBB becomes recurrent, then further investigations are required to rule out the other conditions such as subtle immunodeficiencies or other causes of chronic suppurative lung ...
Îòâåòèòü ñ öèòèðîâàíèåì
  #221  
Ñòàðûé 02.10.2020, 11:05
Àâàòàð äëÿ eduardshraibman
eduardshraibman eduardshraibman âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 20.10.2010
Ãîðîä: hadera
Ñîîáùåíèé: 17,871
Ñêàçàë(à) ñïàñèáî: 15
Ïîáëàãîäàðèëè 9,328 ðàç(à) çà 8,902 ñîîáùåíèé
eduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
íåîïåðàòèâíîå ëå÷åíèå î.àïïåíäèöèòà

ïðîñòî ïåäèàòðàì äëÿ ñâåäåíèÿ
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Nonoperative management — Although appendectomy for early appendicitis remains the treatment of choice for many surgeons and caregivers, nonoperative treatment (NOM) of early appendicitis may be appropriate in selected children and according to patient and caregiver preference. Specifically, it may be safe and effective for older children who can better describe their symptoms (over six years of age) and have features of early appendicitis as follows [33]:

●Abdominal pain for <48 hours

●White blood cell (WBC) count ≤18,000/microL

●Normal C-reactive protein

●No appendicolith present on imaging

●Appendix diameter ≤1.1 cm on imaging

●No preoperative concern for rupture based upon clinical findings


NOM should only be performed by a surgeon with pediatric expertise. Only a minority of children presenting with appendicitis are potential candidates for NOM. For example, in one large, nonrandomized, multicenter trial, approximately 20 percent of children presenting with appendicitis met similar criteria .However, NOM may be especially appropriate in children who meet the above criteria and who have comorbidities that raise the risk of appendectomy.

Antibiotic protocols vary widely but typically include 1 to 2 days of inpatient broad spectrum IV therapy (eg, piperacillin-tazobactam, ceftriaxone and metronidazole, or ciprofloxacin and metronidazole) until resolution of symptoms and normalization of WBC count occur followed by oral antibiotics (eg, amoxicillin-clavulanic acid or ciprofloxacin and metronidazole) as an outpatient

Êîììåíòàðèè ê ñîîáùåíèþ:
Dr.Vad îäîáðèë(à):
Igoryaka îäîáðèë(à):
Îòâåòèòü ñ öèòèðîâàíèåì
  #222  
Ñòàðûé 03.11.2020, 11:37
svd1 svd1 âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 29.04.2011
Ãîðîä: Íîâîñèáèðñê
Ñîîáùåíèé: 43
Ñêàçàë(à) ñïàñèáî: 3
Ïîáëàãîäàðèëè 8 ðàç(à) çà 8 ñîîáùåíèé
svd1 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåsvd1 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåsvd1 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ïðåäñòàâëåí ñðàâíèòåëüíûé àíàëèç èñïîëüçîâàíèÿ èáóïðîôåíà è ïàðàöåòàìîëà ó äåòåé äî äâóõ ëåò-
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Êîììåíòàðèè ê ñîîáùåíèþ:
eduardshraibman îäîáðèë(à):
Dr.Vad îäîáðèë(à):
ggg650 îäîáðèë(à):
Îòâåòèòü ñ öèòèðîâàíèåì
  #223  
Ñòàðûé 08.02.2021, 20:21
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,291
Ïîáëàãîäàðèëè 33,191 ðàç(à) çà 31,541 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
íå òàê ÷òîáû íîâàÿ èíôà, íî íà ñëàéäàõ ìíîãî ïîëåçíîé èíôû ïî äåòñêèì íîðìàì è àíåìèÿì ñ êåéñàìè

Pediatric Anemias 2013

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Êîììåíòàðèè ê ñîîáùåíèþ:
Igoryaka îäîáðèë(à):
ggg650 îäîáðèë(à):
Âëîæåíèÿ
Òèï ôàéëà: pdf pediatric anemias 11-7-13.pdf (3.16 Ìá, 54 ïðîñìîòðîâ)
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #224  
Ñòàðûé 09.03.2021, 18:44
svd1 svd1 âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 29.04.2011
Ãîðîä: Íîâîñèáèðñê
Ñîîáùåíèé: 43
Ñêàçàë(à) ñïàñèáî: 3
Ïîáëàãîäàðèëè 8 ðàç(à) çà 8 ñîîáùåíèé
svd1 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåsvd1 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåsvd1 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
"Êðàòêîñðî÷íàÿ àíòèìèêðîáíàÿ òåðàïèÿ äåòñêîé âíåáîëüíè÷íîé ïíåâìîíèè" - [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Êîììåíòàðèè ê ñîîáùåíèþ:
eduardshraibman îäîáðèë(à):
Dr.Vad îäîáðèë(à):
Igoryaka îäîáðèë(à):
Îòâåòèòü ñ öèòèðîâàíèåì
  #225  
Ñòàðûé 18.04.2021, 22:32
Àâàòàð äëÿ eduardshraibman
eduardshraibman eduardshraibman âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 20.10.2010
Ãîðîä: hadera
Ñîîáùåíèé: 17,871
Ñêàçàë(à) ñïàñèáî: 15
Ïîáëàãîäàðèëè 9,328 ðàç(à) çà 8,902 ñîîáùåíèé
eduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
äëÿ íàïîìèíàíèÿ,ñåðîëîãèÿ ïðè EBV èíôåêöèè. ñûëêå åñòü cxåìà,êîãäà è êàêèå àíòèòåëà óâåëè÷èâàþòñÿ è ñíèæàþòñÿ
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Êîììåíòàðèè ê ñîîáùåíèþ:
Igoryaka îäîáðèë(à):
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 12:47.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.